InNexus Bio gets patent protecting novel cell penetrating DXL antibodies
InNexus Biotechnology Inc, a drug development company commercialising the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, announced on March 6, 2009 that it has received a notice of allowance on patent claims in the United States (Serial No. 11/119,404) and a patent grant in India (National Phase Application No. 2424/CHENP/2005) further expanding its protection of InNexus’ DXLTM technology.
Speaking on the announcement, InNexus Chairman and CEO, Jeff Morhet said, “DXL™ antibodies that penetrate directly into cells, is an exciting achievement for InNexus and our industry. As we’ve continued to expand our patent portfolio and discover new technologies to develop products, the team has aggressively pursued patent protection for our novel inventions. Patents are the currency of our industry and a driver for enhanced value for our shareholders and potential use of these cell penetrating DXL™ antibodies represents another frontier for the use of antibodies for therapeutic and diagnostic applications.”
Dr. Thomas Kindt, Chief Scientific Officer of InNexus said, “The claims in these patents are directed toward the addition of membrane transport sequences to DXL antibodies, which facilitate penetration of DXL™ antibodies into cancer cells. The ability to direct our DXL™ antibodies to intracellular targets by the addition of a membrane transport sequence, imparts great therapeutic potential in a number of applications. The patents and applications also include coverage for new molecules and products of InNexus. We like to say we build better antibodies and today, we demonstrated that once again”.
Source: Innexus Biotechnology Inc.